Preview Newsletter

XARELTO Media Monitoring – Week of 10-23-15

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Number of Lawsuits Filed in MDL Rising
Oct 16, 2015 | Press Advantage
By Marc Goldich

BloodThinnerHelp.com reports today on the updated number of lawsuits that are filed in the Xarelto MDL. Over the past few months the number of lawsuits that are filed in the federal multidistrict litigation, or MDL, has significantly increased. More than 400 additional lawsuits have been consolidated, bringing the total to 1,231 as of August 17, 2015. This is a huge increase for the Xarelto MDL because on July 15, 2015 only 805 lawsuits were consolidated. It is an even larger increase from the number filed in June which rested at about 500. For more detailed information on the status of the Xarelto lawsuits, click here.
Xarelto Lawsuits: A Detailed Overview
Oct 17, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on the full details surrounding Xarelto and the lawsuits associated with the product. Xarelto (rivaroxaban) is a blood thinner or anticoagulant that prevents blood from clotting. It is commonly used to prevent deep vein thrombosis or other blood clot complications that can occur after surgeries like hip or knee replacements. At times, it is also used to treat patients with atrial fibrillation, which is a disorder in which the heart beats with irregular rhythm. In these cases, Xarelto is given in order to lower the risk of stroke due to blood clots.
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed in Vermont
Oct 19, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports today on one of the more significant lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. This particular lawsuit is a part of the recent wave of lawsuits that are being filed across the country that similarly allege that the blood thinner Xarelto causes uncontrollable internal bleeding which can lead to severe injuries, hospitalization, and in many cases, death. This lawsuit was filed in Vermont federal court on July 25, 2014 under the case number 2:14-CV-00159-CR. The full complaint can be downloaded and read here.
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed in Vermont
Oct 19, 2015 | WDRB-TV
By Marc Goldich

BloodThinnerHelp.com reports today on one of the more significant lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. This particular lawsuit is a part of the recent wave of lawsuits that are being filed across the country that similarly allege that the blood thinner Xarelto causes uncontrollable internal bleeding which can lead to severe injuries, hospitalization, and in many cases, death. This lawsuit was filed in Vermont federal court on July 25, 2014 under the case number 2:14-CV-00159-CR. The full complaint can be downloaded and read here.
Xarelto Lawsuit Update: Increasing Number of Cases Filed in Phila. Mass Tort Group
Oct 20, 2015 | KEYC-TV
By Marc Goldich

BloodThinnerHelp.com reports today with the updated number of cases in the Philadelphia mass tort Xarelto litigation. The mass tort group in Philadelphia was formed after a motion was made to consolidate the rising number of cases in the area with similar allegations against the same defendants, the manufacturers of the blood thinner Xarelto, Bayer AG and Janssen Pharmaceuticals.
PA Xarelto Lawsuit Cites New Allegations
Oct 20, 2015 | KHQ-TV
By Marc Goldich

BloodThinnerHelp.com reports on a Xarelto Lawsuit that has come out of Pennsylvania State Court versus Janssen Pharmaceuticals alleging that the manufacturer’s one-size-fits-all, once-daily dosage for the drug does not remain effective for a full 24-hour period.
Xarelto Lawsuit Filed By Ohio Victim With GI Bleed
Oct 16, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports that a woman from Ohio who suffered gastrointestinal bleeding after taking Xarelto for atrial fibrillation joins several others filing lawsuits against the drug. She claims that it caused her internal bleeding as well as connected health issues within just two months of use. Her lawsuit was filed in the United States District Court for the Southern District of Ohio.
Xarelto Lawsuits Expose Lack Of Antidote
Oct 22, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on Xarelto blood thinner and lawsuits concerning its lack of antidote. Older blood thinners, such as Warfarin (Coumadin) are able to be counteracted with the use of vitamin K. This is extremely important to physicians, because it means that patients using the blood thinner who experience bleeding episodes are able to be treated.
Ohio Woman Files Xarelto Lawsuit
Oct 23, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports that a Xarelto lawsuit has been filed in Ohio. Xarelto came on the market in 2011, after being approved by the U.S. Food and Drug Administration as a revolutionary new blood thinner. Over the past 4 years, the drug has grossed over $1 billion in yearly sales, and has become the most popular anticoagulant on the market. Much of its initial popularity is attributed to the fact that, unlike older blood thinners, the drug does not require regular monitoring and adjustments to the dosage by physicians. It is a one-size-fits all drug, providing consumers with more freedom.

Plaintiff Attorney Blogs

Is Xarelto Potentially Linked to Increased Risk of Liver Injury?
Oct 16, 2015 | Schmidt National Law Group
By Erica Arvanitis

Health Canada recently completed a safety review of Xarelto, an anti-coagulant medication manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. According to a Summary Safety Review, which was released on August 26, 2015, the department investigated the drug after two studies showed Xarelto was potentially connected to liver injury in 16 patients. The goal was to find out if the drug could increase risk of liver injury, however so far they don’t have a clear answer. Some of the reports failed to contain complete information. Due to ongoing concerns, Health Canada has asked healthcare professionals and patients to report any liver injury that could be linked to Xarelto.
Xarelto Lawsuit Alleges Drug Isn’t Effective, Even When Taken as Directed
Oct 16, 2015 | The Legal Examiner
By Steven Davis

A lawsuit filed last week in Pennsylvania state court against Janssen Pharmaceuticals alleges that the company’s recommended once a day dosage for the blockbuster drug Xarelto isn’t effective for a full 24 hours. A plaintiff with non-valvular atrial fibrillation who suffered a stroke four days after starting on Xarelto filed the lawsuit in Philadelphia on October 8. The suit alleges that the indicated 20mg dose of the medication is insufficient to protect against stroke/systemic embolism for those who take the medication once a day.
Xarelto – Blood Thinner Lawsuit
Oct 16, 2015 | Baron & Budd

A blood thinner such as Xarelto is not supposed to cause health problems – it is supposed to help prevent them. However, patients have reported serious complications with Xarelto, which has been linked to severe internal bleeding that has sometimes been fatal. The Xarelto attorneys with Baron & Budd may be able to help if you or a loved one has been harmed by this blood thinner medication.
Yet Another Xarelto Lawsuit Filed in Ohio
Oct 18, 2015 | LawyersandSettlements.com
By Gordon Gibb

Expectations that Xarelto, a blood thinner, would emerge to become a blockbuster drug were well-founded. In the four years since rivaroxoaban was approved for use by the US Food and Drug Administration (FDA) in 2011, Xarelto has achieved annual sales of over $1 billion in the United States alone, according to conservative estimates. The anticoagulant has also grabbed the largest market share for all anticoagulants. However, the success achieved by Johnson & Johnson and Bayer is not without controversy over Xarelto Bleeding complications and other side effects.
Xarelto Lawsuit: Blood Thinner Caused Pulmonary Bleeding
Oct 19, 2015 | Top Class Actions
By Robert J. Boumis

A new lawsuit has joined numerous others against Jannsen Pharmaceuticals, the makers of the popular anticoagulant Xarelto. Plaintiff Harry K. of Texas filed the Xarelto lawsuit, alleging that Xarelto is inherently more dangerous than other drugs of its type, leading to life-threatening medical complications.
Xarelto Lawsuit Attorney Notes Recent Lawsuit
Oct 20, 2015 | American Injury Attorney Group

A Xarelto lawsuit attorney notes a recently filed lawsuit against makers of the anticoagulant Xarelto, alleging that the companies misled patients and doctors about the safety and efficacy of the drug, Xarelto lawyers note. If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Pennsylvania Xarelto Lawsuit Puts Forth Unique Allegations
Oct 20, 2015 | Bernstein Liebhard LLP
By Sandy Liebhard

A new Xarelto lawsuit pending in Pennsylvania has put forth allegations unique to the other claims pending in the state’s mass tort litigation. According to court documents, the October 8th filing contends that the blood thinner isn’t always effective for 24 hours, even when taken as directed. The complaint was filed on behalf of a man who was prescribed the standard 20mg daily dose of Xarelto to prevent strokes associated with nonvalvular atrial fibrillation. Just four days after initiating treatment, he suffered a stroke.
Xarelto Lawsuit Update: Pretrial Orders for Phila. Mass Tort Group Released
Oct 21, 2015 | The Legal Herald
By Marc Goldich

New pre-trial orders have been issued for the Philadelphia mass tort group that is consolidating Xarelto internal bleeding lawsuits. A new pretrial order was issued for the Philadelphia mass tort litigation against the manufacturers of the blood thinner Xarelto. This pretrial order, Case Management Order no.7, was issued on August 21, 2015 and appoints a Discovery Master for the Xarelto Litigation Mass Tort Program. The new Discovery Master is listed as the Honorable Jane Cutler Greenspan. This order is applicable to all cases filed in the mass tort litigation in the Civil Trial Division of the Philadelphia Court of Common Pleas. The investigation process for evidence before a trial begins is referred to as the discovery process.
Xarelto Advertisements Failed to Disclose the Reality of Risks, Lawsuit Alleges
Oct 22, 2015 | Texas Injury Blog
By Majed Nachawati

Many Xarelto lawsuits that have been filed against Johnson & Johnson and Bayer Corporation allege that the pharmaceutical companies failed to disclose the reality of the blood thinner's risks and dangers. Xarelto has been prescribed as a blood thinner to treat many conditions, from nonvalvular atrial fibrillation, deep vein thrombosis, to pulmonary embolism. The favorable studies that center on the drug's positive outcomes are also at question, due to the many cases of uncontrolled bleeding that sometimes lead to death in Xarelto patients nationwide. Other patients have suffered strokes, retinal hemorrhages, epidural hematoma, intracranial hemorrhages, hemoglobin decrease, gastrointestinal hemorrhages, and adrenal bleeding.
Xarelto Caused Man to Suffer 2 Bleeding Events, Lawsuit Says
Oct 22, 2015 | Top Class Actions
By Paul Tassin

A new claim by a Texas couple accuses Janssen Pharmaceuticals and Johnson & Johnson of overpromoting their blood thiner Xarelto. Plaintiffs Walter and Sue P. of Texas are bringing claims against Janssen Pharmaceuticals Inc., Johnson & Johnson, Bayer Healthcare Pharmaceuticals Inc., and their related companies, all of whom are involved in the development, manufacture or sale of the anticoagulant medication Xarelto.

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Number of Lawsuits Filed in MDL Rising

Oct 16, 2015 | Press Advantage

By Marc Goldich

BloodThinnerHelp.com reports today on the updated number of lawsuits that are filed in the Xarelto MDL. Over the past few months the number of lawsuits that are filed in the federal multidistrict litigation, or MDL, has significantly increased. More than 400 additional lawsuits have been consolidated, bringing the total to 1,231 as of August 17, 2015. This is a huge increase for the Xarelto MDL because on July 15, 2015 only 805 lawsuits were consolidated. It is an even larger increase from the number filed in June which rested at about 500. For more detailed information on the status of the Xarelto lawsuits, click here.
Lawsuits Allege Xarelto is Dangerous:
These lawsuits are consolidated into the MDL because they all commonly allege that the anticoagulant Xarelto can cause serious, uncontrollable internal bleeding which leads to severe injury and even death. The lawsuits also allege that the manufacturers of the drug were aware of the dangers of the drug yet released it to market anyway and did not sufficiently warn patients and doctors about the risks associated with its usage.
Xarelto was first released onto the United States market in 2011 after it was approved by the Food and Drug Administration, FDA, to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone a hip or knee replacement surgery. Xarelto is a part of a new class of blood thinners known as Xa inhibitors and the active drug in Xarelto is rivaroxaban. The manufacturers of Xarelto, drug conglomerates Bayer AG and Janssen Pharmaceuticals, marketed Xarelto as a safe and convienent alternative to the traditional blood thinner Warfarin. Unlike Warfarin, Xarelto does not require constant blood monitoring or a restrictive diet.
The lawsuits filed allege that Xarelto is not as safe as Warfarin because there is no antidote for the anticoagulant effects of Xarelto. This means that if a patient taking Xarelto suffers an internal bleeding event, it can become dangerous very quickly and turn into an uncontrollable bleed because there is no drug available to reverse the effects of Xarelto and make the blood clot.
Because of these dangers, Xarelto currently has two ‘black box’ warnings attached to it by the FDA. The black box warning is the strictest warning that the FDA can attach to a drug short of recalling it. It means that there is a reasonable risk of harm associated with the drug. For a full list of the FDA warnings regarding Xarelto, clickhere.
“If you believe that you or a loved one were harmed by Xarelto usage, contact us immediately.” Xarelto attorney Marc Goldich said, “If the manufacturers of the drug were aware of the dangers and put the drug to market anyway, they deserve to be brought to justice.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
https://www.pressadvantage.com/story/4739-xarelto-lawsuit-update-number-of-lawsuits-filed-in-mdl-rising

Return to headline | Return to top
Xarelto Lawsuits: A Detailed Overview

Oct 17, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on the full details surrounding Xarelto and the lawsuits associated with the product. Xarelto (rivaroxaban) is a blood thinner or anticoagulant that prevents blood from clotting. It is commonly used to prevent deep vein thrombosis or other blood clot complications that can occur after surgeries like hip or knee replacements. At times, it is also used to treat patients with atrial fibrillation, which is a disorder in which the heart beats with irregular rhythm. In these cases, Xarelto is given in order to lower the risk of stroke due to blood clots.
Although Xarelto was approved by the Food and Drug Administration and released across the nation in 2011, there have been significant reports of serious health complications occurring in patients using the drug. These reports are so significant, in fact, that one study found that 73% of 16,041 patients studied who were taking Xarelto had experienced some sort of adverse effect, such as anemia or issues with internal bleeding.
Internal bleeding can occur easily due to minor injuries, a fall, or even a woman’s menstrual cycle. These are not typically serious issues, as blood is designed to clot and therefore stop the bleeding. When patients taking blood thinners are injured and bleeding, however, their blood cannot clot and likewise cannot stop. This can quickly create a dangerous situation with many health risks, including death. Other older blood thinning drugs on the market enable physicians to reverse their blood thinning effects if a patient has suffered an injury, which would once again allow the blood to clot. Xarelto, however, is part of a newer line of blood thinners termed Xa inhibitors, and is only treatable by extreme life saving measures, such as blood transfusions.
Because of the health complications experienced by many Xarelto patients, lawsuits began being filed in January of 2014. Additionally, the FDA issued two ‘black box’ warnings regarding the safety of the product. Black box warnings are considered the most strict warnings possible, and are the last resort before fully removing a drug from the market. Warnings and precautions include mention of issues such as increased risk of thrombotic events, spinal/epidural hematoma, and uncontrollable bleeding that is unable to be treated by “a specific antidote.”
Today, the Xarelto lawsuits that were filed on a federal level have been consolidated into a multidistrict litigation, or MDL, in Louisiana. Other lawsuits were filed across the nation, though not federally, and have been consolidated in certain state courts, such as Pennsylvania. As a whole, many of the lawsuits allege the same complaints: that Xarelto causes internal bleeding that is not able to be controlled or stopped, which can lead to serious injuries, hospitalization, and even death. Additionally, complaints allege that the manufacturers of Xarelto, (Bayer AG, and Janssen Pharmaceuticals), knew of the dangers associated with their product and released the drug to the market anyway, generating over $1 billion in product sales in 2013 alone.
Trials concerning the MDL for Xarelto are scheduled to start the first half of 2017. They will be presided over by Judge Fallon. As of the beginning of September of 2015, there were about 1,231 cases consolidated, however, additional lawsuits are expected to appear before the trials begin.
Those who have experienced serious health complications after using Xarelto may be entitled to a lawsuit and owed compensation. Attorneys are currently assisting with this nation-wide effort, and are happy to discuss the case. For more information or to ask any questions, please contact Marc Goldich, Esq. anytime at (866) 425-8902.
http://www.digitaljournal.com/pr/2710785?noredir=1#ixzz3pKTLCRB8

Return to headline | Return to top
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed in Vermont

Oct 19, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports today on one of the more significant lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. This particular lawsuit is a part of the recent wave of lawsuits that are being filed across the country that similarly allege that the blood thinner Xarelto causes uncontrollable internal bleeding which can lead to severe injuries, hospitalization, and in many cases, death. This lawsuit was filed in Vermont federal court on July 25, 2014 under the case number 2:14-CV-00159-CR. The full complaint can be downloaded and read here.
Lawsuit Alleges Xarelto Caused Wrongful Death:
This Vermont lawsuit was filed by the daughter of a man who is deceased due to internal bleeding complications allegedly caused by Xarelto. The man was prescribed Xarelto to treat his atrial fibrillation, a heart condition that can cause blood clots and stroke. The complaint details that the man was prescribed Xarelto on July 17, 2012 and continued to take Xarelto as directed for a few weeks. The man was eventually admitted to the hospital and diagnosed with a parenchymal hemorrhage. Because the man was taking Xarelto at the time and it was active in his system, his blood did not clot. Unfortunately, he died from an uncontrollable internal bleeding event on August 1, 2012. He was hospitalized for a total of six days. The lawsuit alleges that the deceased’s Xarelto usage was the cause of the man’s unfortunate death.
The daughter of the deceased is bringing this lawsuit forward to gain compensation for her father’s wrongful death. She is the administrator of his estate and is seeking damages for pain and suffering, medical bills from his treatment, probate, legal fees, funeral and burial expenses, and other expenses that are related to the probate of his estate. The lawsuit makes the allegation that if they had known the risks of an irreversible internal bleed, they would have chosen a different drug than Xarelto because there were safer alternatives on the market. They also allege that the manufacturers of Xarelto were reckless and negligent by releasing the product to the market and that the drug was the cause of the injuries that the deceased suffered and his death.
Xarelto’s Dangerous Lack of Antidote:
This lawsuit and other similar lawsuits filed allege that Xarelto is more dangerous than other blood thinners on the market because Xarelto does not have a corresponding antidote. This means that if a patient suffers an internal bleeding injury, such as the deceased in this lawsuit did, there is no way to reverse the anticoagulant effects of Xarelto and stop the bleeding. The FDA has released several warnings regarding Xarelto usage which can be found here.
“If you believe that you or a loved one were harmed by Xarelto, we urge you to contact us immediately,” Xarelto attorney Marc Goldich said. “Cases are being filed all across the country and yours could be next.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.digitaljournal.com/pr/2712397#ixzz3pKTcOxNh

Return to headline | Return to top
Xarelto Lawsuit Update: New Wrongful Death Lawsuit Filed in Vermont

Oct 19, 2015 | WDRB-TV

By Marc Goldich

BloodThinnerHelp.com reports today on one of the more significant lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. This particular lawsuit is a part of the recent wave of lawsuits that are being filed across the country that similarly allege that the blood thinner Xarelto causes uncontrollable internal bleeding which can lead to severe injuries, hospitalization, and in many cases, death. This lawsuit was filed in Vermont federal court on July 25, 2014 under the case number 2:14-CV-00159-CR. The full complaint can be downloaded and read here.
Lawsuit Alleges Xarelto Caused Wrongful Death:
This Vermont lawsuit was filed by the daughter of a man who is deceased due to internal bleeding complications allegedly caused by Xarelto. The man was prescribed Xarelto to treat his atrial fibrillation, a heart condition that can cause blood clots and stroke. The complaint details that the man was prescribed Xarelto on July 17, 2012 and continued to take Xarelto as directed for a few weeks. The man was eventually admitted to the hospital and diagnosed with a parenchymal hemorrhage. Because the man was taking Xarelto at the time and it was active in his system, his blood did not clot. Unfortunately, he died from an uncontrollable internal bleeding event on August 1, 2012. He was hospitalized for a total of six days. The lawsuit alleges that the deceased’s Xarelto usage was the cause of the man’s unfortunate death.
The daughter of the deceased is bringing this lawsuit forward to gain compensation for her father’s wrongful death. She is the administrator of his estate and is seeking damages for pain and suffering, medical bills from his treatment, probate, legal fees, funeral and burial expenses, and other expenses that are related to the probate of his estate. The lawsuit makes the allegation that if they had known the risks of an irreversible internal bleed, they would have chosen a different drug than Xarelto because there were safer alternatives on the market. They also allege that the manufacturers of Xarelto were reckless and negligent by releasing the product to the market and that the drug was the cause of the injuries that the deceased suffered and his death.
Xarelto’s Dangerous Lack of Antidote:
This lawsuit and other similar lawsuits filed allege that Xarelto is more dangerous than other blood thinners on the market because Xarelto does not have a corresponding antidote. This means that if a patient suffers an internal bleeding injury, such as the deceased in this lawsuit did, there is no way to reverse the anticoagulant effects of Xarelto and stop the bleeding. The FDA has released several warnings regarding Xarelto usage which can be foundhere.
“If you believe that you or a loved one were harmed by Xarelto, we urge you to contact us immediately,” Xarelto attorney Marc Goldich said. “Cases are being filed all across the country and yours could be next.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.wdrb.com/story/30300327/xarelto-lawsuit-update-new-wrongful-death-lawsuit-filed-in-vermont

Return to headline | Return to top
Xarelto Lawsuit Update: Increasing Number of Cases Filed in Phila. Mass Tort Group

Oct 20, 2015 | KEYC-TV

By Marc Goldich

BloodThinnerHelp.com reports today with the updated number of cases in the Philadelphia mass tort Xarelto litigation. The mass tort group in Philadelphia was formed after a motion was made to consolidate the rising number of cases in the area with similar allegations against the same defendants, the manufacturers of the blood thinner Xarelto, Bayer AG and Janssen Pharmaceuticals.
There are currently 430 cases filed in the mass tort group and this number is expected to rise as litigation continues. Currently, the litigation is only in the pretrial stages and the trials are not expected to start for quite some time. We will post updates on the Xarelto litigation on our website here as we receive them.
Lawsuits Allege Xarelto is Dangerous:
The lawsuits are able to be consolidated into a mass tort group because they all make similar allegations against the same defendants. These lawsuits all similarly allege that Xarelto causes severe internal bleeding which can lead to serious injury or death in patients using the drug, that the manufacturers of Xarelto failed to adequately warn patients and doctors about the real dangers of the drug, and that the manufacturers of the drug were reckless in releasing the product to market without an antidote. A full list of the lawsuits filed can be found here.
Xarelto’s Alleged Design Defect:
Xarelto is a part of a new class of blood thinners called Xa inhibitors. Xa inhibitors work differently from the traditional blood thinners on the market because they prevent clots by blocking the agent in blood that makes it clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood’s ability to clot. This is very dangerous considering the drug does not have an antidote to its anticoagulant effects. This means that if a patient suffers from an internal bleeding injury there is no way to stop the bleeding short of extreme life saving medical interventions. This is very different from the situation that patients are in if they are taking the drug Warfarin, a historically successful blood thinner. If a patient experiences an internal bleeding injury while taking Warfarin, a doctor can administer Vitamin K, the effects of Warfarin will be reversed, and the blood will clot again. Since Xarelto’s release, the FDA has issued several warnings regarding the safety of the drug and the drug has two ‘black box’ warnings attached to it. The black box warning is the most strict warning the FDA can attach to the drug short of recalling it and it usually means that there is a reasonable risk of harm associated with usage of the drug.
“If you believe that you or a loved one have been harmed by Xarelto usage, contact us immediately.” Xarelto attorney Marc Goldich said, “Cases against the drug’s manufactures are being filed all across the country, yours could be next.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.keyc.com/story/30311651/xarelto-lawsuit-update-increasing-number-of-cases-filed-in-phila-mass-tort-group

Return to headline | Return to top
PA Xarelto Lawsuit Cites New Allegations

Oct 20, 2015 | KHQ-TV

By Marc Goldich

BloodThinnerHelp.com reports on a Xarelto Lawsuit that has come out of Pennsylvania State Court versus Janssen Pharmaceuticals alleging that the manufacturer’s one-size-fits-all, once-daily dosage for the drug does not remain effective for a full 24-hour period.
A PA plaintiff suffering from atrial fibrillation suffered a stroke just four days after starting Xarelto. On October 8th, 2015, the plaintiff filed a suit alleging that the drug had proven to be ineffective in preventing their stroke. While this is the first complaint of its kind against the drug, it is not the first to allege that a one-size-fits-all dosage is problematic.
This lawsuit, alleging that Xarelto was not only ineffective at preventing a stroke, but may have actually contributed to causing the stroke, joins many others which allege that the medication has dangerous side effects for consumers.
The drug, originally thought of as a revolutionary new type of blood thinner, was approved by the U.S. Food and Drug Administration in 2011 to prevent strokes for those with atrial fibrillation or to treat patients after surgery to ensure that they do not experience blood clots such as deep vein thrombosis or pulmonary embolism. Consumers appreciated the idea of a blood thinner which, unlike prior blood thinners on the market, did not require them to be seen by their physician for regular evaluations.
There are well over 1,000 lawsuits against the anti-coagulant drug and its manufacturers, many of which discuss the fact that this drug has no antidote. When patients taking older versions of blood thinners experienced bleeding, physicians are able to apply a vitamin K treatment, which counter the effects of the blood thinner and allow the patient’s blood to clot. Xarelto, however, cannot be stopped with vitamin K and patients who experience side effects require life-saving measures such as blood transfusions when experiencing uncontrollable bleeding.
In 2014, the United States Judicial Panel on Multidistrict Litigation consolidated the lawsuits that had been filed against the drug, announcing that they would be seen before U.S. District Judge Eldon E. Fallon in Louisiana. The bellwether trials for these cases are supposed to begin in August of 2016. As patients taking Xarelto continue to experience uncontrollable bleeding episodes, these numbers are expected to continue to rise.
“If you or a loved one have taken Xarelto and suffered serious health complications, you may be entitled to compensation,” said Xarelto attorney Marc Goldich.“It is not too late to join the current lawsuits and explore your rights,” he continued.
Marc Goldich, Esq. helps to work individuals suffering after using Xarelto on a regular basis. He also sponsors BloodThinnerHelp.com, a website resource dedicated to helping individuals negatively affected by the drug to seek help. Anyone who has questions about Xarelto or would like to look into their rights further should contact Marc Goldich, Esq. at their convenience for a completely free and completely confidential consultation. Simply call 877-635-5876.
http://www.khq.com/story/30311672/pa-xarelto-lawsuit-cites-new-allegations

Return to headline | Return to top
Xarelto Lawsuit Filed By Ohio Victim With GI Bleed

Oct 16, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports that a woman from Ohio who suffered gastrointestinal bleeding after taking Xarelto for atrial fibrillation joins several others filing lawsuits against the drug. She claims that it caused her internal bleeding as well as connected health issues within just two months of use. Her lawsuit was filed in the United States District Court for the Southern District of Ohio.
Xarelto is a drug thinner, but is alleged to be more dangerous than older types of drug thinners, because it has no antidote. When patients taking other blood thinners suffer injuries and are bleeding, physicians are able to administer vitamin K treatments which counteract the blood thinners, allowing the blood to clot. New-version blood thinners like Xarelto, however, do not respond to vitamin K.
Xarelto (also known as rivaroxaban), was FDA approved in 2011 as what was thought to be a revolutionary new substitute for Coumadin (warfarin). It was designed to help reduce the risk of blood clots for patients known to be at risk for pulmonary embolism, strokes, or deep vein thrombosis, and was also commonly used to treat atrial fibrillation. The drug’s sales quickly skyrocketed, reaching over $1 billion across America.
After many consumers began to use the new drug, lawsuits and injury allegations also began to appear, spurring the FDA to provide severe “black box” warnings about the product.
Presiding Judge Fallon will see the consolidated and centralized lawsuits, currently numbering around 2,000, and has now set bellwether trials which are anticipated to be reviewed by juries in the later half of 2017. The lawsuits filed are against manufacturers Johnson & Johnson and Bayer. According to documents, the first two of the four trials will be held on February 6th, 2017 and March 13, 2017. These will be seen in the Eastern District of Louisiana. Other trial locations will include Mississippi and Texas.
“The number of lawsuits associated with Xarelto use are expected to continue growing,” stated Xarelto attorney Marc Goldich. “We urge individuals who have suffered from health issues after using the drug to contact us, so that they are able to evaluate their cases and potentially seek compensation for their suffering.”
Those who are interested in exploring their rights concerning the Xarelto lawsuits, or have questions regarding the subject, please contact Marc Goldich, Esq. by calling 866-425-8902 at their convenience.
http://www.digitaljournal.com/pr/2710641

Return to headline | Return to top
Xarelto Lawsuits Expose Lack Of Antidote

Oct 22, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on Xarelto blood thinner and lawsuits concerning its lack of antidote.
Older blood thinners, such as Warfarin (Coumadin) are able to be counteracted with the use of vitamin K. This is extremely important to physicians, because it means that patients using the blood thinner who experience bleeding episodes are able to be treated.
Vitamin K can be found in nature, primarily in many leafy green vegetables, such as lettuce, broccoli, and spinach. After an individual ingests these foods, the bacteria found within their intestines produce vitamin K. Vitamin K is essential to helping the blood within their bodies clot, and therefore, it becomes something essential for anyone taking the blood thinner Warfarin to become more aware of.
Warfarin works by changing the way an individual's body uses vitamin K, and interfering with the clotting properties of the vitamin. It significantly slows down the clotting process. Patients using Warfarin, however, then need to keep careful watch on their vitamin K intake, to maintain proper balance. When using this blood thinner, clients are required to visit their physician frequently, to complete testing and make adjustments to the medication dosage.
When individuals who use Warfarin experience uncontrollable bleeding, this medication provides doctors with the option of treating the patient with vitamin K, which reverses the effects of the medicine and allows their blood to clot, potentially saving their life.
Xarelto came on the market as a one-size-fits-all medication, and patients requiring blood thinner medications were given new freedoms with the drug, which does not require physician monitoring. Unfortunately, however, this new blood thinner does not respond to vitamin K treatments, so if a patient taking Xarelto experiences unstoppable bleeding, doctors do not have the option of using vitamin K to counter the effects of the drug and allow the patient’s blood to clot. Instead, in these instances, physicians have to resort to life-saving measures, like blood transfusions.
Blood thinners are commonly prescribed to people with atrial fibrillation or those who have recently undergone hip or knee replacement surgeries and are at increased risk for blood clots. While all blood thinners are considered to be dangerous, Xarelto has been recently named the most dangerous, due to its lack of antidote.
Those who would like more information concerning this topic or the lawsuits that now surround Xarelto should reach out to Marc Goldich, Esq. at any time by calling (866)-425-8902.
“Those who have been negatively impacted after using these drugs deserve compensation, and I have been working to help many people research their rights concerning Xarelto,” said Xarelto attorney Marc Goldich.

Return to headline | Return to top
Ohio Woman Files Xarelto Lawsuit

Oct 23, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports that a Xarelto lawsuit has been filed in Ohio. Xarelto came on the market in 2011, after being approved by the U.S. Food and Drug Administration as a revolutionary new blood thinner. Over the past 4 years, the drug has grossed over $1 billion in yearly sales, and has become the most popular anticoagulant on the market. Much of its initial popularity is attributed to the fact that, unlike older blood thinners, the drug does not require regular monitoring and adjustments to the dosage by physicians. It is a one-size-fits all drug, providing consumers with more freedom.
The same things that have contributed to the drug's popularity, however, also seem to be causing it troubles. Use of Xarelto is now commonly connected to many negative allegations concerning significantly heightened effects of unstoppable bleeding, and complications associated with this condition.
Recently, another Xarelto lawsuit was filed, this time in the state of Ohio. In this case, the plaintiff is a woman who said that she was originally prescribed the drug in order to treat atrial fibrillation. Several months after using Xarelto, however, she claims to have developed gastrointestinal bleeding.
Bleeding episodes are considered significantly dangerous for anyone using blood thinners, however, they are considered especially dangerous for consumers using Xarelto. This is because unlike other older blood thinners, Xarelto has no known antidote. Generally speaking, this means that if someone who has been using Xarelto has uncontrollable bleeding, the doctors are able to do nothing to reverse the effects of the drug and make that individual’s blood clot. Instead, they are required to resort to life-saving measures like blood transfusions.
Older blood thinners, such as Warfarin, allow patients experiencing bleeding episodes to be treated with vitamin K, which can counteract the effects of the drug and allow an individual’s blood to clot. During serious episodes of bleeding, this antidote can be a lifesaving difference, preventing the patient from suffering from a fatal hemorrhage. Xarelto will not respond to vitamin K in this way.
As lawsuits against Xarelto continue to be filed, they have been consolidated in the U.S. District Court for the Eastern District of Louisiana. They are being overseen by the Honorable Judge Eldon Fallon, who has currently asked those involved to prepare four bellwether trials to be reviewed in 2017. With almost 2,000 lawsuits currently filed, this will help to avoid duplicate discovery and allow litigation to move quickly and efficiently.
Anyone who has suffered from bleeding issues after using the anticoagulant Xarelto may be entitled to legal compensation. It is not too late to join this litigation. Marc Goldich is a Xarelto lawyer who works to help individuals explore their rights concerning the pending litigation. Those who have questions or would like to further evaluate their own rights may contact Marc Goldich, Esq. directly at (866) 425-8902.
http://www.digitaljournal.com/pr/2718368

Return to headline | Return to top

Plaintiff Attorney Blogs

Is Xarelto Potentially Linked to Increased Risk of Liver Injury?

Oct 16, 2015 | Schmidt National Law Group

By Erica Arvanitis

Health Canada recently completed a safety review of Xarelto, an anti-coagulant medication manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. According to a Summary Safety Review, which was released on August 26, 2015, the department investigated the drug after two studies showed Xarelto was potentially connected to liver injury in 16 patients. The goal was to find out if the drug could increase risk of liver injury, however so far they don’t have a clear answer. Some of the reports failed to contain complete information. Due to ongoing concerns, Health Canada has asked healthcare professionals and patients to report any liver injury that could be linked to Xarelto.
Xarelto and the FDA
The FDA approved Xarelto in 2011 in order to help reduce the risk of blood clots in patients undergoing hip and knee replacement surgery. Later, it was approved to help decrease the risk of stroke in patients with non-valvular atrial fibrillation. Xarelto has been connected to an increased risk of gastrointestinal bleeding, which can lead to hospitalization and even death.
Xarelto Liver Studies
The studies that alerted Health Canada to the possibility of a link between Xarelto and liver injury:
The first study, published in 2014, doctors reported in the JAMA Internal Medicine journal that two patients developed serious liver problems while taking Xarelto. This included “massively elevated transaminase activity levels and hyperbilirubinemia.” After ceasing taking the drug, the patients recovered quickly. The authors of the study added that between 2008 and 2013, 42 cases of liver injury possibly related to the ingestion of Xarelto were reported to the Swiss Agency of Therapeutic Products. In the end, it was concluded that treatment with Xarelto could be linked with “severe, symptomatic liver injury.”
The second study, published in the Journal Hepatology, reported on 14 cases of liver injury linked to Xarelto. Researchers searched databases for similar cases, and discovered “a considerable number of additional hepatic [liver related] adverse events where rivaroxaban was reported as a suspected cause.” They recommended additional studies be done to determine the risks of liver injury associated with Xarelto, and told doctors to be aware for symptoms of liver disease in patients who are taking the drug.
Xarelto Concerns High
Health Canada stated that at the time of their investigation, the Canada Vigilance Program received 61 reports of liver-related adverse events in patients taking Xarelto. While further research of the cases didn’t reveal a clear cause-and-effect relationship linked to the drug, Health Canada noted that some of the reports contained only partial information.
The department also researched international data from the World Health Organization (WHO), and discovered 431 cases of liver injury in patients taking Xarelto, with 23 of the patients only taking Xarelto, and no other medication.
http://www.nationalinjuryhelp.com/dangerous-drugs/xarelto-potentially-linked-increased-risk-liver-injury/

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Isn’t Effective, Even When Taken as Directed

Oct 16, 2015 | The Legal Examiner

By Steven Davis

A lawsuit filed last week in Pennsylvania state court against Janssen Pharmaceuticals alleges that the company’s recommended once a day dosage for the blockbuster drug Xarelto isn’t effective for a full 24 hours.
A plaintiff with non-valvular atrial fibrillation who suffered a stroke four days after starting on Xarelto filed the lawsuit in Philadelphia on October 8. The suit alleges that the indicated 20mg dose of the medication is insufficient to protect against stroke/systemic embolism for those who take the medication once a day.
The Pennsylvania case is believed to be the first in the nation to make the allegation that Xarelto is not effective in preventing, and in some cases actually contributing to, ischemic strokes in patients suffering from atrial fibrillation.
What is Xarelto?
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011, and is currently being prescribed to prevent strokes in people with atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.
Xarelto is currently the only new anticoagulant that is recommended by the manufacturer for once-a-day dosing for patients with atrial fibrillation. Rival anticoagulants require users to take multiple doses per day and in some situations, to undergo monitoring.
Xarelto MDL
Late in 2014, the U.S. Judicial Panel on Multidistrict Litigation (MDL) announced that all nationwide Xarelto lawsuits filed in federal courts would be consolidated in the Eastern District of Louisiana before U.S. District Judge Eldon E. Fallon. Plaintiffs in those cases claim that Xarelto caused uncontrollable and sometimes fatal bleeding in patients.
Recent numbers show that there are more than 400 Xarelto-related cases currently pending, and experts estimate that eventually several thousand cases will be transferred into the MDL.
http://chicago-land.legalexaminer.com/fda-prescription-drugs/xarelto-lawsuit-alleges-drug-isnt-effective-even-when-taken-as-directed/

Return to headline | Return to top
Xarelto – Blood Thinner Lawsuit

Oct 16, 2015 | Baron & Budd

A blood thinner such as Xarelto is not supposed to cause health problems – it is supposed to help prevent them. However, patients have reported serious complications with Xarelto, which has been linked to severe internal bleeding that has sometimes been fatal. The Xarelto attorneys with Baron & Budd may be able to help if you or a loved one has been harmed by this blood thinner medication.
What is Xarelto, and Why is it Dangerous?
Xarelto is one of the “new generation” of blood thinners marketed as an alternative to Warfarin (marketed under the brand name of Coumadin). For decades, Warfarin was the only choice for people at risk for forming blood clots. The drawback is that patients on Warfarin need to undergo continual monitoring to ensure the medication is working correctly. Patients who take Xarelto, on the other hand, do not have to be monitored nearly as often.
The downside – one that can potentially be fatal – is that if a patient on Xarelto experiences excessive bleeding there is no way to stop it. If this event happens to someone taking Warfarin, a doctor can administer large doses of vitamin K to thicken the blood. This antidote is not available for those taking Xarelto, and as a result there is a substantial risk of bleeding to death.
Other Side Effects of Xarelto May Include:
Adrenal Bleeding
Blood Clots
Brain Hemorrhages
Epidural Hematoma
External Bleeding
Gastrointestinal Hemorrhage
Internal Bleeding
Intracranial Hemorrhage
Kidney Failure
Liver Damage
Retinal Hemorrhage
Stroke
Xarelto and the FDA
The U.S. Food and Drug Administration (FDA) originally approved Xarelto for patients who were having hip or knee replacement in order to lower the chances they would develop blood clots. The agency would later approve the drug for several other uses, such as the treatment of deep vein thrombosis and pulmonary embolism. Xarelto is also approved for patients who have atrial fibrillation, a type of irregular heartbeat.
But studies have shown the dangers of the drug and the FDA has reacted. In fact, Xarelto’s own website shows that nearly 75 percent of people who participated in a study experienced bleeding events, anemia and other serious problems. Those who took higher doses were more susceptible to bleeding.
The FDA sent the marketer of Xarelto, Johnson & Johnson, a warning letter in 2013 stating that a print ad the company was running was misleading because it minimized the risks associated with taking the medication. In 2014, the agencyissued a warning stating that people who suddenly stop taking the drug could be at risk for blood clots.
There is currently no recall of Xarelto due to internal bleeding, but the investigation into the drug is still ongoing. It can often take a long time to bring out all the facts necessary to stimulate a recall, whether it is voluntary or involuntary.
Why Should You File a Xarelto Lawsuit?
There are very few ways that a person can hold a pharmaceutical company accountable for harmful actions, and a Xarelto lawsuit is one of them. If you take legal action, you may be able to obtain compensation for lost wages and medical costs related to Xarelto complications.
Many patients took the drug without the slightest idea that the drug did not have an antidote. The main reason for this is that neither Johnson & Johnson nor Xarelto manufacturer Bayer warned patients or doctors of this risk. Instead of making sure that people knew of the risks, Bayer and Johnson & Johnson promoted the benefits instead.
People file Xarelto lawsuits for many reasons. For example, they may have experienced emotional distress due to having to care for a loved one harmed by the drug. Others sue because of financial hardships such as medical bills and lost wages. Still others take legal action due to the emotional and financial issues caused by the death of a loved one after a Xarelto complication.
Lawsuits can take many years, and settlements may not be forthcoming until several cases are tried in front of juries and drug manufacturers realize how much of a financial risk they face. However, that does not mean you can wait to file a lawsuit; you have a certain period of time where you can take legal action for any injuries you either sustained or may sustain in the future. This statute of limitations is a major reason you need to speak with an experienced attorney as soon as you can.
https://baronandbudd.com/health/pharmaceuticals/xarelto-blood-thinner-lawsuit/

Return to headline | Return to top
Yet Another Xarelto Lawsuit Filed in Ohio

Oct 18, 2015 | LawyersandSettlements.com

By Gordon Gibb

Expectations that Xarelto, a blood thinner, would emerge to become a blockbuster drug were well-founded. In the four years since rivaroxoaban was approved for use by the US Food and Drug Administration (FDA) in 2011, Xarelto has achieved annual sales of over $1 billion in the United States alone, according to conservative estimates. The anticoagulant has also grabbed the largest market share for all anticoagulants. However, the success achieved by Johnson & Johnson and Bayer is not without controversy over Xarelto Bleeding complications and other side effects.

To that end, one of the latest Xarelto lawsuits was filed earlier this month in Ohio. Plaintiff Molly Harr, in her Xarelto lawsuit, claims that she was prescribed Xarelto for treatment of atrial fibrillation (AFib). By November of that year, Harr was experiencing gastrointestinal bleeding.

When Xarelto and one other new-age blood thinner came onto the scene, there was much anticipation considering the new drugs represented the first significant update to blood thinners since the traditional standby Coumadin (warfarin) first appeared on the market more than 50 years ago, rising to become the gold standard for treatment of AFib.

But not without frustration, given the constant monitoring of blood and diet in order to keep the balance right and Coumadin working properly. Warfarin proved a lot of work for both patient and health care provider, and the medical community has for years been looking for an easier, more convenient and more effective alternative that would prove less of a strain on the health care system simply in terms of monitoring.

That panacea finally arrived with the appearance of Xarelto and one other new-age blood thinner, Pradaxa. Both products touted the capacity to dispense with the need for constant blood monitoring. Doctors embraced the dynamic duo in droves - hence the impressive sales figures for Xarelto.

But that enthusiasm has since been tempered given the lack of a handy antidote to deploy should a Xarelto Bleeding Issue occur. Warfarin is blessed with an Achilles heel: vitamin K. In the event of a severe bleeding issue resulting from blood that has perhaps thinned a bit too effectively, the introduction of vitamin K has the ability to quickly reverse the thinning properties of warfarin, saving a patient from a potentially fatal hemorrhage.

There is no such antidote for Xarelto, although one is in development. The fact remains however that Xarelto was granted FDA approval without a similar means to reverse its blood-thinning properties in the same way as warfarin. What’s more, say plaintiffs, the claim for less monitoring effectively adds to the danger, or so it is alleged. Plaintiffs claim that defendants were negligent in promoting the need for less stringent monitoring given the inability to stem a Xarelto Bleedout in similar fashion to warfarin.

Many a Xarelto lawsuit has alleged significant injury, and even Xarelto death.
Xarelto lawsuits have been consolidated in the US District Court, Eastern District of Louisiana before US District Judge Eldon Fallon, who is preparing for four bellwether trials in 2017. While the trial dates have been set, the cases have not been chosen. However, there are plenty to choose from in the pool: as of mid-September, there were no fewer than 1,710 lawsuits alleging grievous Xarelto Side Effects consolidated in multidistrict litigation. That number will be narrowed down to a pool of 40, from which the four bellwether cases will be selected, likely by this coming January.

The latest lawsuit, filed in Ohio, is Molly A. Harr et al v. Janssen Research & Development LLC f/k/a/Johnson and Johnson Pharmaceutical Research and Development LLC, et al, Case No. 1:2015cv00647 filed October 5, 2015 in Ohio Southern District Court.
http://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-27-20979.html#.Vik3gn6rRD8

Return to headline | Return to top
Xarelto Lawsuit: Blood Thinner Caused Pulmonary Bleeding

Oct 19, 2015 | Top Class Actions

By Robert J. Boumis

A new lawsuit has joined numerous others against Jannsen Pharmaceuticals, the makers of the popular anticoagulant Xarelto.
Plaintiff Harry K. of Texas filed the Xarelto lawsuit, alleging that Xarelto is inherently more dangerous than other drugs of its type, leading to life-threatening medical complications.
Xarelto is an anticoagulant, or blood thinner, that prevents dangerous blood clots. All anticoagulants carry some risk, but plaintiffs in Xarelto lawsuits claim that Xarelto carries the risk of working too well.
When this happens, the body cannot form blood clots to stop the bleeding and patients are at risk of serious injury from uncontrollable bleeding.
In severe cases, a patient can bleed to death from very minor injuries, including tiny internal injuries common in the lungs and GI tract.
Xarelto Lawsuit
Harry’s Xarelto lawsuit explains how his physicians prescribed him Xarelto in 2013. Shortly after, he found himself in the hospital with a life-threatening case of pulmonary bleeding. The bleeding caused Harry severe pain and suffering, required expensive medical care, and interfered with his income.
A key allegation of Harry’s Xarelto lawsuit is that the drug is inherently defective and more dangerous than other anticoagulants. The Xarelto lawsuit further alleges that it is fraudulently promoted as safer than other anticoagulants on the market.
One of the big differences between Xarelto and older anticoagulants is the lack of a reversal agent. If a patient taking an older anticoagulant like Warfarin experience pulmonary bleeding or other types of uncontrollable bleeding, doctors can use a second drug, the reversal agent, to effectively shut down the anticoagulant.
Unlike older, off-patent anticoagulants, Xarelto has no known reversal agent. Harry K’s Xarelto lawsuit holds that this makes Xarelto more dangerous than similar drugs on the market, and to promote its use, the lawsuit alleges, is criminally fraudulent.
So many Xarelto lawsuits have been filed that the court system has resorted to a process called multidistrict litigation, or MDL, to coordinate them. In MDL, similar cases are grouped together and coordinated to avoid duplication of costly efforts.
Since Xarelto lawsuits typically hinge on similar evidence and make similar accusations against the makers of Xarelto, these lawsuits are ideal for inclusion in a single Xarelto MDL.
The Xarelto Lawsuit is Harry K. vs. Janssen Research & Development, LLC, et al, case No. 1753, within the larger Xarelto MDL In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/190675-xarelto-lawsuit-alleges-drug-caused-pulmonary-bleeding/

Return to headline | Return to top
Xarelto Lawsuit Attorney Notes Recent Lawsuit

Oct 20, 2015 | American Injury Attorney Group

A Xarelto lawsuit attorney notes a recently filed lawsuit against makers of the anticoagulant Xarelto, alleging that the companies misled patients and doctors about the safety and efficacy of the drug, Xarelto lawyers note.
If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Important: The time you have to pursue a claim is limited. Contact us for more information.
Lawsuit: Doctors and Patients Were Misled
Xarelto is a commonly used blood thinner that treats and prevents blood clots and also lowers the risk of stroke in patients who have atrial fibrillation. The May 2015 court filing states that the drug makers, Bayer Corporation, Johnson & Johnson and its subsidiary, Janssen Research and Development, exaggerated the effectiveness of Xarelto to encourage physicians to prescribe it over other drugs, and that they also allegedly placed advertisements based on studies that were flawed, poorly managed or even deemed unreliable by the Food and Drug Administration (FDA).
The lawsuit additionally claims that the drug makers withheld information about the risks associated with using Xarelto. The plaintiffs allege the drug makers were aware that Xarelto could cause excessive blood thinning and life-threatening bleeding when used twice per day, and that they also knew that there was no effective antidote to reverse these dangerous side effects. However, this information was not made known to physicians, patients or the FDA.
The lawsuit contends that the drug makers are strictly liable for the injuries that patients suffered while using Xarelto. The plaintiffs are seeking punitive damages in addition to compensatory damages.
Injured Patients May Be Entitled to Compensation
If a drug maker fails to fulfill its duty to provide safe drugs and to warn of potentially harmful side effects that may be associated with its medication, it could be held liable for any injuries that may result.
Patients who have been injured by Xarelto may be entitled to compensation for damages, including:
Medical expenses
Pain, suffering, and mental anguish
Loss of income or ability to work
If a patient dies from complications after taking Xarelto, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:
Pain, suffering, and mental anguish from the loss of a loved one
Loss of financial support of a loved one
Funeral expenses
Affected patients are encouraged to speak with a Xarelto lawsuit attorney to learn more about their rights and remedies.
Contact Us For More Information
If you or a loved one took Xarelto and suffered complications, including internal bleeding, contact the American Injury Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.
When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.
See our Frequently Asked Questions page for more information, and contact the American Injury Attorney Group today.
https://attorneygroup.com/blog/xarelto-lawsuit-attorney/

Return to headline | Return to top
Pennsylvania Xarelto Lawsuit Puts Forth Unique Allegations

Oct 20, 2015 | Bernstein Liebhard LLP

By Sandy Liebhard

A new Xarelto lawsuit pending in Pennsylvania has put forth allegations unique to the other claims pending in the state’s mass tort litigation. According to court documents, the October 8th filing contends that the blood thinner isn’t always effective for 24 hours, even when taken as directed.
The complaint was filed on behalf of a man who was prescribed the standard 20mg daily dose of Xarelto to prevent strokes associated with nonvalvular atrial fibrillation. Just four days after initiating treatment, he suffered a stroke.
Xarelto Litigation
The Pennsylvania case appears to be the first in the nation to question the effectiveness of standard Xarelto treatment in preventing strokes. But like other Xarelto lawsuits pending in Pennsylvania and elsewhere, the complaint also questions marketing claims that plaintiffs allege wrongly positioned the new-generation blood thinner as a superior alternative to warfarin. Warfarin, sold under the brand Coumadin, has been in use for several decades.
Currently, more than 400 product liability claims are pending in the Xarelto mass tort litigation now underway in the Philadelphia Court of Common Pleas. Nearly 1,700 federal cases have also been filed in a multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana. The vast majority of these cases were brought on behalf of plaintiffs who allegedly suffered serious Xarelto bleeding events, such as gastrointestinal or cerebral hemorrhage.
All blood thinners pose a risk of serious internal bleeding. But Xarelto lawsuits point out that warfarin bleeding can be stopped via the administration of vitamin K. By contrast, there is currently no approved antidote to stop internal hemorrhaging caused by Xarelto. Plaintiffs also claim that most Xarelto patients would benefit from regular blood monitoring to ensure that dosage is maintained at an optimum level, something the drug’s manufacturers say is not necessary.
Xarelto is currently the only novel blood thinner that recommends once-daily dosing for atrial fibrillation patients. Other blood thinners on the market require multiple doses each day, and some even recommend that patients undergo regular blood monitoring.
Contact a Xarelto Lawyer Today
The Xarelto lawyers at Bernstein Liebhard LLP are currently representing individuals who suffered serious bleeding events allegedly related to the use of this drug. If you would like to file a similar Xarelto lawsuit, please contact our office by calling (888) 979-1182.
http://www.thexareltolawsuit.com/pennsylvania-xarelto-lawsuit-puts-forth-unique-allegations/

Return to headline | Return to top
Xarelto Lawsuit Update: Pretrial Orders for Phila. Mass Tort Group Released

Oct 21, 2015 | The Legal Herald

By Marc Goldich

New Pre-Trial Orders for Xarelto Phila Mass Tort Group
New pre-trial orders have been issued for the Philadelphia mass tort group that is consolidating Xarelto internal bleeding lawsuits. A new pretrial order was issued for the Philadelphia mass tort litigation against the manufacturers of the blood thinner Xarelto. This pretrial order, Case Management Order no.7, was issued on August 21, 2015 and appoints a Discovery Master for the Xarelto Litigation Mass Tort Program. The new Discovery Master is listed as the Honorable Jane Cutler Greenspan. This order is applicable to all cases filed in the mass tort litigation in the Civil Trial Division of the Philadelphia Court of Common Pleas. The investigation process for evidence before a trial begins is referred to as the discovery process. It is common for complex litigation cases to appoint a discovery master. The discovery master has the power to implement and manage a plan for the discovery process, issue orders to resolve discovery disagreements, submit recommendations to the presiding judge, and in general monitor the discovery process. The role of the discovery master is more of a management role than a judiciary role in the trial process.
The Xarelto Litigation
There are currently 430 cases filed in the Philadelphia mass tort litigation. These cases are able to be consolidated because they all make similar allegations against the same defendants, in these cases the manufacturers of the blood thinner Xarelto, Bayer AG and Janssen Pharmaceuticals. The lawsuits all commonly allege that the blood thinner Xarelto causes severe internal bleeding which can lead to serious injuries and death in patients. They also allege that the manufacturers did not adequately warn patients and doctors about the real risks of the drug and were reckless and negligent by releasing the drug to market without an antidote.
Lawsuits Allege Xarelto is More Dangerous
Xarelto is a part of a new class of blood thinners called Xa inhibitors. Xa inhibitors work differently than other blood thinners on the market because they keep the blood from clotting by blocking the chemical in the blood that is responsible for making it clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood's ability to clot. This is dangerous because the manufacturers of Xarelto did not develop an antidote to counteract the drug's anticoagulant effects, meaning that if a patient experiences an internal bleeding injury while Xarelto is active in their system, there is no way to stop the bleeding. This is a much more dangerous situation than the one that patients taking Warfarin are in. If a patient suffers an internal bleeding injury while taking Warfarin, a doctor can administer vitamin K and the patient's blood will clot again. "If the manufacturers of Xarelto were aware of the dangers of the drug yet released it to market anyway, they deserve to be brought to justice." Xarelto attorney Marc Goldich said, "Do not hesitate to contact us if you believe that you or a loved one have been harmed by Xarelto." For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

Return to headline | Return to top
Xarelto Advertisements Failed to Disclose the Reality of Risks, Lawsuit Alleges

Oct 22, 2015 | Texas Injury Blog

By Majed Nachawati

Many Xarelto lawsuits that have been filed against Johnson & Johnson and Bayer Corporation allege that the pharmaceutical companies failed to disclose the reality of the blood thinner's risks and dangers. Xarelto has been prescribed as a blood thinner to treat many conditions, from nonvalvular atrial fibrillation, deep vein thrombosis, to pulmonary embolism. The favorable studies that center on the drug's positive outcomes are also at question, due to the many cases of uncontrolled bleeding that sometimes lead to death in Xarelto patients nationwide. Other patients have suffered strokes, retinal hemorrhages, epidural hematoma, intracranial hemorrhages, hemoglobin decrease, gastrointestinal hemorrhages, and adrenal bleeding.
Legal Commentary
Fears Nachawati's Xarelto attorneys are studying, examining and investigating Xarelto claims on behalf of people and their families who may have been injured by the drug. Although no monetary amount can compensate for the loss of a loved one, a successful claim against the responsible parties will enable the victim’s family to cover any medical or final expenses, so that they may focus on the grieving process during this trying time. If you or a loved one experienced any side effects while taking Xarelto, contact our Xarelto lawyers to discuss the facts of your potential case. We are available by phone for a free consultation at +1.866.813.1662 or by email at mn@fnlawfirm.com.
About the Author
Majed Nachawati is a dedicated Xarelto Lawyer who represents victims and families harmed by dangerous drugs nationwide. Mr. Nachawati has resolved numerous pharmaceutical cases successfully, resulting in seven and eight figure confidential settlements. Texas Monthly Magazine named him as a Super Lawyer for the past six years. He is a member of a Leaders' Forum and a Board of Directors member for the Texas Trial Lawyers Association. He is also a member of the Board of Directors for Public Justice, a PAC member of the American Association for Justice, and the Grievance Committee for the State Bar of Texas. Mr. Nachawati holds licenses to practice law in the Northern, Southern, and Eastern Districts of Texas. Mr. Nachawati can be reached through his website athttp://cases.fnlawfirm.com/xarelto, by email at mn@fnlawfirm.com or by calling +1.866.813.1662.
http://www.txinjuryblog.com/2015/10/articles/dangerous-drugs/xarelto-advertisements-failed-to-disclose-the-reality-of-risks-lawsuit-alleges/

Return to headline | Return to top
Xarelto Caused Man to Suffer 2 Bleeding Events, Lawsuit Says

Oct 22, 2015 | Top Class Actions

By Paul Tassin

A new claim by a Texas couple accuses Janssen Pharmaceuticals and Johnson & Johnson of overpromoting their blood thiner Xarelto.
Plaintiffs Walter and Sue P. of Texas are bringing claims against Janssen Pharmaceuticals Inc., Johnson & Johnson, Bayer Healthcare Pharmaceuticals Inc., and their related companies, all of whom are involved in the development, manufacture or sale of the anticoagulant medication Xarelto.
Walter says he began taking Xarelto around May 2013. According to his Xarelto lawsuit, Walter suffered two internal bleeding events in May and November of that year. Both bleeding events were life-threatening and required hospitalization and blood transfusions, he says.
Walter now says these two bleeding events were caused by the Xarelto he took. He argues that the defendants made certain misstatements in their promotional material for Xarelto and concealed certain important information about the risk of Xarelto bleeding.
Had Walter known otherwise, he says, he would have taken extra precautions during his Xarelto treatment or would not have used Xarelto at all.
Xarelto Bleeding Risks
At issue in this and other Xarelto lawsuits is the risk of excessive bleeding that comes with Xarelto treatment. Xarelto, or rivaroxaban, is a product of Janssen Pharmaceuticals and its parent company Johnson & Johnson.
It’s commonly used to prevent stroke and systemic embolism in persons with non-valvular atrial fibrillation. It’s also approved by the FDA to treat deep vein thrombosis and pulmonary embolism, and to prevent their recurrence. It also reduces the risk of deep vein thrombosis in patients undergoing hip and knee replacement surgery.
Along with Pradaxa and Eliquis, Xarelto is one of a new generation of anticoagulants that recently entered a market that had been dominated for decades by the anticoagulant warfarin, also sold under the brand name Coumadin.
Though Coumadin is still the most frequently prescribed drug for treatment of atrial fibrillation, Xarelto is in second place. Sales of Xarelto reached $2 billion dollars in 2013.
Excessive, Misleading Xarelto Advertising
Walter and Sue argue that the defendants over-promoted Xarelto’s efficacy and understated its risks. They say the defendants spent at least $11 million in 2013 alone on advertisements in medical journals and on direct-to-consumer advertising.
This campaign touted what the defendants called the “Xarelto Difference,” which referred to the fact that unlike warfarin, Xarelto used an easier once-daily dosage and did not require ongoing blood monitoring.
However, the plaintiffs also cite research that suggests both dosage adjustments and blood monitoring might be warranted in the course of Xarelto treatment. The advertising also does not mention the fact that, unlike with warfarin, there is no antidote to the anticoagulation effects of Xarelto. Once excessive Xarelto bleeding starts, there is no complimentary medication or “reversal agent” that can get it under control.
They also cite a June 2013 letter from the FDA asking the defendants to cease production of a particular print ad that the agency described as “false or misleading because it minimizes the risks associated with Xarelto” and could mislead consumers about the necessity of dose adjustments.
Sue, Walter’s spouse, is bringing her own claim for loss of consortium. Loss of consortium is a legal claim that the spouse of a victim can bring to seek compensation for the harm done to the marital relationship. It can cover more concrete losses like loss of services and financial support, and it can also compensate for losses not as easily quantified, such as loss of affection and emotional support.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/196527-couple-texas-sues-xarelto-bleeding/

Return to headline | Return to top

Add recipients

Suggested